Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources

This article was originally published in The Pink Sheet Daily

Executive Summary

Growth of post-market surveillance system also may require more resources.

Advertisement

Related Content

FDA Aims To Tap Sentinel Data Network For Drug Effectiveness Studies
Califf Continues Clinical Trial Reform Crusade With Confirmation Vote Pending
Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups
PDUFA VI: Breakthrough Issues Among FDA Priorities
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
Social Media Site Could Help FDA Track Adverse Events
Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue
PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers

Topics

Advertisement
UsernamePublicRestriction

Register

PS078004

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel